These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34585213)

  • 1. Commentary: The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice.
    Gauthier S; Rosa-Neto P
    J Prev Alzheimers Dis; 2021; 8(4):411. PubMed ID: 34585213
    [No Abstract]   [Full Text] [Related]  

  • 2. Aducanumab: Appropriate Use Recommendations.
    Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
    J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: Aducanumab: Appropriate Use Recommendations.
    Scheltens P; Vijverberg EGB
    J Prev Alzheimers Dis; 2021; 8(4):412-413. PubMed ID: 34585214
    [No Abstract]   [Full Text] [Related]  

  • 4. Aducanumab, amyloid, and culture wars.
    Iliffe S; Manthorpe J
    BMJ; 2021 Aug; 374():n2038. PubMed ID: 34413026
    [No Abstract]   [Full Text] [Related]  

  • 5. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research.
    Doody R
    J Prev Alzheimers Dis; 2021; 8(4):393-395. PubMed ID: 34585210
    [No Abstract]   [Full Text] [Related]  

  • 7. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel.
    Gerding H; Monés J; Tadayoni R; Boscia F; Pearce I; Priglinger S
    Br J Ophthalmol; 2015 Mar; 99(3):297-304. PubMed ID: 25075121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label use of aducanumab for cerebral amyloid angiopathy.
    Greenberg SM; Cordonnier C; Schneider JA; Smith EE; van Buchem MA; van Veluw SJ; Verbeek MM; Viswanathan A; Werring DJ
    Lancet Neurol; 2021 Aug; 20(8):596-597. PubMed ID: 34237272
    [No Abstract]   [Full Text] [Related]  

  • 11. Alzheimer disease and aducanumab: adjusting our approach.
    Selkoe DJ
    Nat Rev Neurol; 2019 Jul; 15(7):365-366. PubMed ID: 31138932
    [No Abstract]   [Full Text] [Related]  

  • 12. NCCN news.
    J Natl Compr Canc Netw; 2012 May; 10(5):xv-xxi. PubMed ID: 22720326
    [No Abstract]   [Full Text] [Related]  

  • 13. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.
    Arndt JW; Qian F; Smith BA; Quan C; Kilambi KP; Bush MW; Walz T; Pepinsky RB; Bussière T; Hamann S; Cameron TO; Weinreb PH
    Sci Rep; 2018 Apr; 8(1):6412. PubMed ID: 29686315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aducanumab: look before leaping.
    Perlmutter JS
    Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
    [No Abstract]   [Full Text] [Related]  

  • 15. From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation.
    Frost CV; Zacharias M
    Proteins; 2020 Dec; 88(12):1592-1606. PubMed ID: 32666627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 18. Standard-of-care testimony: best practices or reasonable care?
    Simon RI
    J Am Acad Psychiatry Law; 2005; 33(1):8-11. PubMed ID: 15809234
    [No Abstract]   [Full Text] [Related]  

  • 19. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 20. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.